Form 8-K - Current report:
SEC Accession No. 0001104659-24-131705
Filing Date
2024-12-26
Accepted
2024-12-26 16:01:47
Documents
14
Period of Report
2024-12-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2432018d1_8k.htm   iXBRL 8-K 29009
2 EXHIBIT 10.1 tm2432018d1_ex10-1.htm EX-10.1 84436
  Complete submission text file 0001104659-24-131705.txt   309875

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA carm-20241224.xsd EX-101.SCH 3018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE carm-20241224_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE carm-20241224_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2432018d1_8k_htm.xml XML 3684
Mailing Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36296 | Film No.: 241581010
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)